Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04022213 · ClinicalTrials.gov registry record · Phase 2
A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum
A Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
- 1
- Study location
NCT04022213: Active Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04022213 is a Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 31 participants, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04022213, a Phase 2 study of Peritoneal Cancer and Desmoplastic Small Round Cell Tumor, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in the body, and how effective it is in treating cancer. 131I-Omburtamab is not approved by the FDA to treat DSRCT or other cancers of the peritoneum.
Primary Outcome
Progression free survival after RIT + WA-IMRT.
Conditions Studied
Interventions
- DRUG 131 I-omburtamab
- RADIATION WAP-IMRT
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2019-07-15 |
| Est. Completion | 2026-07 |
| Phase | Phase 2 |
What the registry record for NCT04022213 still lists
NCT04022213 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 154-participant average among 32 other Peritoneal Cancer trials with a reported enrollment target (80% lower).
The record links to 3 conditions, with Peritoneal Cancer appearing as the primary indexed condition, and to 2 interventions - of which 131 I-omburtamab is the first listed.
NCT04022213 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04022213 about?
NCT04022213 is a clinical study titled "A Study of the Drug I131-Omburtamab in People With Desmoplastic Small Round Cell Tumors and Other Solid Tumors in the Peritoneum". The purpose of this study is to test any good and bad effects of the study drug 131I-omburtamab. 131I-omburtamab could prevent the cancer from returning, or delay the cancer from getting worse, but it could also cause side effects. Researchers hope to learn more about how 131I-omburtamab works in th...
What is the current status of trial NCT04022213?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2019-07-15. Estimated completion is 2026-07.
What conditions does trial NCT04022213 study?
This clinical trial studies the following conditions: Peritoneal Cancer, Desmoplastic Small Round Cell Tumor, Peritoneal Carcinoma.
What interventions are being tested in trial NCT04022213?
The interventions under investigation include: 131 I-omburtamab (DRUG), WAP-IMRT (RADIATION).
Who is sponsoring clinical trial NCT04022213?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04022213 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peritoneal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04022213's enrollment target sits among peer trials
31 23rd of 32 higher than 10 of 32 other Peritoneal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Peritoneal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
An Evaluation of Maintenance Therapy Combination Mirvetuximab Soravtansine and Olaparib
RECRUITING · Phase 2
-
Study of Acute Normovolemic Hemodilution (ANH) in People With Ovarian Cancer Who Are Having Cytoreductive Surgery
RECRUITING · Phase 2
-
A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.
ACTIVE NOT RECRUITING · Phase 2
-
A Phase II Study Of Nivolumab/ Bevacizumab/Rucaparib
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Rucaparib in Patients With Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2)
COMPLETED · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI